Facial Diplegia: A Rare, Atypical Variant of Guillain-Barré Syndrome and Ad26.COV2.S Vaccine

Authors

Esha Jain, American University of Antigua
Krunal Pandav, Larkin Community Hospital
Pratima Regmi, CUNY College of Staten Island
George Michel, Larkin Community Hospital
Ida Altshuler, Richmond University Medical Center

Document Type

Article

Publication Date

7-25-2021

Abstract

This potentially life-threatening disease poses an interesting perspective on adverse events that can occur or can be exacerbated following the Ad26.COV2.S (Johnson & Johnson) vaccine. The authors report findings in a 65-year-old female patient who experienced facial diplegia, an atypical variant of Guillain-Barré syndrome, two weeks after receiving the Ad26.COV2.S vaccine against coronavirus disease 2019. Post-approval pharmacovigilance of each vaccine helps better understand the long-term outcomes, and reporting adverse events is crucial for advancements in medical knowledge.

Comments

This work was originally published in Cureus available at DOI: 10.7759/cureus.16612

This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.